Læknablaðið : fylgirit - 05.01.2015, Qupperneq 54

X V I I V Í S I N D A R Á Ð S T E F N A H Í
F Y L G I R I T 8 2
54 LÆKNAblaðið/Fylgirit 82 2015/101
heldur ekki aukin. Því virðist ekki ástæða til þess hætta notkun þessar
lyfja fyrir hjartaaðgerð.
E 149 Expired and pathogen inactivated platelets support
differentiation of mesenchymal stem cells
Sandra Mjöll Jónsdóttir-Buch1,2, Hildur Sigurgrímsdóttir1,2, Ramona Lieder1, Ólafur
Eysteinn Sigurjónsson1,2,3
1The Blood Bank, Landspítali University Hospital, 2Faculty of Medicine, University of Iceland,
3School of Science and Engineering, Reykjavík University
oes@ru.is
Introduction: Platelet lysates have been reported as suitable cell culture
supplement for cultures of mesenchymal stromal cells (MSCs). The dem-
and for safe and animal-free cultures of MSCs is linked to the potential
application of MSCs in clinics. We have previously demonstrated that
expired platelet concentrates may represent a good source of platelets
for lysate production without competing with blood banks for platelet
donors. Pathogen inactivation treatment of platelet concentrates allows
for prolonged storage up to 7 days and has therefore been implemented
in blood processing facilities worldwide. In this study, we evaluated
the suitability of INTERCEPT treated, expired platelet concentrates,
processed into platelet lysates, for the culture of MSCs compared to non-
treated expired platelets.
Methods and data: Bone marrow-derived MSCs were cultured in media
supplemented with either platelet lysates from traditionally prepared
expired platelet concentrates or in platelet lysates from expired and
pathogen inactivated platelet concentrates. The effects of pathogen
inactivation on the ability of the platelets to support MSCs in culture
were determined by evaluating MSC immunomodulation, immunop-
henotype, proliferation and trilineage differentiation.
Results: Platelet lysates prepared from expired and pathogen inactiva-
ted platelet concentrates supported MSC differentiation and immunos-
uppression better as compared to traditionally prepared platelet lysates
from expired platelet units. Pathogen inactivation of platelets with the
INTERCEPT system prior to use in MSC culture had no negative effects
on MSC immunophenotype or proliferation.
Conclusions: The use of expired pathogen inactivated platelet units
from blood banks to prepare platelet lysates for the culture of MSCs is
desirable and attainable.
E 150 Dánartíðni og sjálfsvíg stuttu eftir útskrift heim af bráðadeild
Vilhjálmur Rafnsson1, Oddný S. Gunnarsdóttir2
1Rannsóknastofu í heilbrigðisfræði, læknadeild Háskóla Íslands, 2vísindadeild Landspítala
vilraf@hi.is
Inngangur: Rannsókn með stuttum fylgitíma sýndi að einkennagreining
á bráðadeild tengist lágri dánartíðni. Markmiðið með framskyggnri
rannsókn var að rannsaka dánartíðni innan 8, 15 og 30 daga eftir útskrift
heim af bráðasviði Landspítalans.
Efniviður og aðferðir: Heildarkomur sjúklinga sem útskrifaðir voru
heim af bráðadeild (ekki innlagðir á legudeild) voru 227.097 á árunum
2002-2008, skráðar voru kennitölur, kyn, aldur, komudagur og ein aðal
sjúkdómsgreining. Upplýsingar um dánarmein voru fengnar úr skrám
Hagstofunnar með samtengingu á kennitölum. Komurnar voru flokk-
aðar eftir sjúkdómsgreiningum í einkennagreiningar (ICD-10, R-kótar)
og aðrar greiningar. Dánartíðni á 100,000 innan 8, 15 og 30 daga, og
tilheyrandi hættuhlutföll (HR) og 95% öryggismörk (CI) voru reiknuð
fyrir öll dánarmein og ákveðin önnur dánarmein.
Niðurstöður: HR vegna allra dánarmeina meðal sjúklinga með einkenn-
agreiningu var 0,64 (95% CI 0,41-1,01) innan átta daga, 0,70 (95% CI
0,50-0,99) innan 15 daga og 0,82 (95% CI 0,65-1,04) innan 30 daga borið
saman við þá með aðrar greiningar. HR innan 30 daga meðal þeirra
með einkennagreiningu við útskrift var 1,48 (95% CI 1,03-2,13) vegna
krabbameina, 3,72 (95% CI 1,44-9,60) vegna sjálfsvíga og 0,50 (95% CI
0,32-0,79) vegna sjúkdóma í blóðrásarkerfi.
Ályktanir: Dauði innan 8 daga frá útskrift var sjaldgæfur atburður.
Andlát sjúklings, stuttu eftir útskrift, sem fengið hafði einkennagrein-
ingu, bendir til að sjúkdómsástand hans hafi ekki verið að fullu rétt
skilið við útskrift. Stefnumunurinn á lágri heildardánartíðni og hárri
dánartíðni vegna sjálfsvíga er vísbending um þetta. Lág dánartíðni
vegna sjúkdóma í blóðrásarkerfi bendir til þess að þeir séu rétt greindir
á bráðadeildinni.
E 151 Metabolomic analysis of platelets during storage
Giuseppe Paglia1, Ólafur E. Sigurjónsson2,3, Óttar Rolfsson1, Morten Bagge Hansen4,
Sigurður Brynjólfsson1, Sveinn Guðmundsson2, Bernhard Ö. Pálsson1
1Center for Systems Biology, University of Iceland, 2Blood Bank, Landspítali University
Hospital, 3School of Science and Engineering, Reykjavík University, 4Department of Clinical
Immunology, Rigshospitalet, Copenhagen University Hospital
oes@ru.is
Introduction: Platelet concentrates (PCs) may be prepared using three
methods; platelet rich plasma, aphaeresis and buffy coat. The aim of this
study was to obtain a comprehensive dataset that describes metabolism
of buffy coat derived platelets during storage and to compare it with a
previously published parallel dataset obtained for aphaeresis-derived
platelets.
Methods and data: During storage we measured more than 150 parame-
ters in 8 platelet units, prepared by the buffy coat method. Samples were
collected at 7 different time points resulting in a dataset containing more
than 8,000 measurements. This dataset was obtained by combining a
series of standard quality control assays in order to monitor the quality
of stored platelets and a deep coverage metabolomics study using liquid
chromatography coupled with mass spectrometry.
Results: Stored platelets showed a distinct metabolic transition occurr-
ing four days after their collection. The transition was evident in platelet
produced by both production methods. Aphaeresis derived platelets
showed a clearer phenotype of platelet activation during early days of
storage. The activated phenotype of aphaeresis PLTs was accompanied
by a higher metabolic activity; especially related to glycolysis and the
TCA cycle. Moreover, the extent of the activation differed between
bags resulting in inter-bag variability in the storage lesion of aphaeresis
prepared PLTs. This may be related to donor related polymorphism.
Conclusions: This study demonstrated two discrete metabolic phenoty-
pes in stored platelets prepared with both aphaeresis and buffy coat
methods. Platelet activation occurs during the first metabolic phenotype
and might lead to a low reproducibility of the aphaeresis PCs.